• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ginkgo Bioworks Holdings, Inc. Class A Common Stock (NY:DNA)

    12.74 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, Oct 28, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ginkgo Bioworks Holdings, Inc. Class A Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday
     
    Via Benzinga
    AI Unlocks Secrets of Intrinsically Disordered Proteins: A Paradigm Shift in Biomedical Design
    A groundbreaking advancement in artificial intelligence has opened new frontiers in understanding and designing intrinsically disordered proteins (IDPs), a class of biomolecules previously considered... 
    Via TokenRing AI
    Topics Artificial Intelligence Derivatives
    Ginkgo Datapoints and Apheris Launch Antibody Developability Consortium
    From Ginkgo Bioworks
    Via Business Wire
    Earnings Scheduled For August 7, 2025
     
    Via Benzinga
    5 Healthcare Stocks On Fire This Week
    Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma. 
    Via Benzinga
    Ginkgo Bioworks Holdings Inc (NYSE:DNA) Fits the Minervini Trend Template with Strong Technicals and High-Growth Momentum
    Ginkgo Bioworks (DNA) meets Minervini Trend Template criteria with strong technicals, earnings growth, and momentum, making it a high-growth stock to watch. 
    Via Chartmill
    Hewlett Packard Enterprise, Magnite, GMS And Other Big Stocks Moving Higher On Monday
     
    Via Benzinga
    Twist Bioscience and Ginkgo Bioworks Revise Collaboration
    From Twist Bioscience Corporation
    Via Business Wire
    Earnings Scheduled For May 6, 2025
     
    Via Benzinga
    Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
    FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods. 
    Via Benzinga
    Topics Animal Testing
    Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
     
    Via Benzinga
    Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
     
    Via Benzinga
    Earnings Scheduled For February 25, 2025
     
    Via Benzinga
    Earnings Scheduled For November 12, 2024
     
    Via Benzinga
    Insights into Ginkgo Bioworks Holdings's Upcoming Earnings
     
    Via Benzinga
    From Promise to Peril: The Downfall of Ginkgo Bioworks
     
    Via Benzinga
    US Stocks Likely To Open Higher Ahead Of Nvidia Earnings: S&P 500's Four-Day Fall Was A 'Non-Event,' Says Expert
    U.S. stock futures rose on Wednesday following two consecutive days of mixed close this week. All futures advanced in premarket trading. 
    Via Benzinga
    Topics Stocks
    Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    What's Going On With Ginkgo Bioworks Stock This Week?
    Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares continue to trade higher after rising nearly 10% on Tuesday. Here's a look at what's going on. 
    Via Benzinga
    Why Ginkgo Bioworks Holdings Stock Raced 9% Higher Today
    The company is forging ahead with next-generation drug development solutions. 
    Via The Motley Fool
    Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development
    Ginkgo Bioworks introduces a protein large language model and API, developed with Google Cloud, to streamline drug discovery by leveraging AI and proprietary biological data, offering affordable and... 
    Via Benzinga
    Topics Artificial Intelligence
    Ginkgo Bioworks Stock Is Rallying Tuesday: Here's Why
    Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are surging Tuesday after the company announced the launch of its new protein large language model (LLM) built on Google Cloud. 
    Via Benzinga
    Compass Minerals, Torrid Holdings, Icahn Enterprises, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday
     
    Via Benzinga
    Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
    Could this beaten-down stock turn things around in the near future? 
    Via The Motley Fool
    2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock
    The risks may resolve in a year or so but seizing the opportunities will take longer. 
    Via The Motley Fool
    This 1 AI Stock Could Revolutionize Biotech and Pharma
    The company is using artificial intelligence, and planning to help others use AI empowered by its data collection. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Down 88% in 1 Year, What's Next for Ginkgo Bioworks Stock?
    Its ambitious business model may not be sustainable. 
    Via The Motley Fool
    Down 86% This Year, Is Ginkgo Bioworks Stock a Bargain Now?
    Have shares of the troubled life sciences business fallen too far? 
    Via The Motley Fool
    Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
    Efficiency in core processes is set to increase substantially due to AI. 
    Via The Motley Fool
    Topics Artificial Intelligence
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.